Rhodojaponin VI ameliorates podocyte injury related with MDM2/Notch1 pathway in rat experimental membranous nephropathy

Abstract

AbstractAimRhodojaponin VI (R‐VI) is the key compound of Rhododendron molle G. Don (Ericaceae) (RM) with effective clinical application in rheumatoid arthritis and chronic glomerulonephritis. In our study, we tried to explore the effect of R‐VI on the rat model of membranous nephropathy.MethodsThe rat model of passive heymann nephritis (PHN) was established by injecting sheep anti‐rat Fx1A serum at a single dose through the tail. The rats were orally administered R‐VI (0.02 mg/kg) or FK506 (1 mg/kg) 1 day before PHN induction, which was kept for 4 weeks. Urine and blood samples as well as kidney tissue were collected for analysis. C5b‐9‐induced human podocyte cell (HPC) was employed for experiments in vitro.ResultsR‐VI could alleviate glomerulonephritis progression and podocyte injury in PHN rats, as indicated by the decreased proteinuria and the elevated level of albumin, accompanied with reduced immune deposits, reversed podocyte injury in the kidneys. Furthermore, R‐VI suppressed murine double minute 2 (MDM2) expression without the alteration in the protein level of p53 and decreased Notch1 expression independent of Numb regulation. Pre‐treatment with R‐VI in C5b‐9‐induced HPC blocked MDM2/Notch1 signalling pathway.ConclusionThus, R‐VI ameliorates podocyte injury in rats with PHN, which was probably related with MDM2/Notch1 signalling pathway.image